EU New Drug Approvals Hit Record High
Total Includes Seven COVID-19 Products
Executive Summary
Chaos wrought by the ongoing coronavirus pandemic. A heavy workload and continuing resource constraints at the European Medicines Agency. Nonetheless, a record number of novel drugs and vaccines were cleared for marketing in the EU last year.
You may also be interested in...
Confronting The Challenges Of Marketing Cell And Gene Therapies
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
EU Health Chief Under Pressure To Explain Delay In Legislative Overhaul
The latest delay to the European Commission’s proposals for revising the EU medicines legislation has caused consternation among members of the European Parliament who do not believe that the hold-up is due simply to a “busy agenda” at the commission.
NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others
There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.